Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top executives said.

Moderna is currently in a late-stage trial for a vaccine for skin cancer. Speaking at an investor conference on Wednesday, President Stephen Hoge said the company’s cancer vaccine could be a “quite large” revenue opportunity that “could come together quite quickly.”

In a mid-stage study released in late 2023, patients with severe skin cancer who got the treatment — a combination of Moderna’s vaccine and Merck’s cancer drug, Keytruda — saw their chances of dying or ...